By Professor Elgene Lim

Book Chapters

Cohen-Hallaleh RB; Rickard M; Lim E; Raymond WA; Segara D; Arnold L; Lee AHS; Schmitt FC; Field A, 2020, 'Clinical Management', in In The International Academy of Cytology Yokohama System for Reporting Breast Fine Needle Aspiration Biopsy Cytopathology Atlas

Field AS; Raymond WA; Rickard MT; Arnold L; Brachtel EF; Chaiwun B; Chen L; Chong PY; Di Bonito L; Hoda RS; Kurtycz DFI; Lee AHS; Lim E; Ljung BM; Michelow P; Osamura RY; Pinamonti M; Sauer T; Segara D; Tse GM; Vielh P; Schmitt F, 2020, 'The International Academy of Cytology Yokohama System for Reporting Breast Fine Needle Aspiration Biopsy Cytopathology: Introduction and Overview', in International Academy of Cytology Yokohama System for Reporting Breast Fine Needle Aspiration Biopsy Cytopathology, pp. 1 - 9, http://dx.doi.org/10.1007/978-3-030-26883-1_1

Saunders C; Jassal S; Lim E, 2019, 'Breast Cancer: The facts', in Breast Cancer: The Facts, Oxford University Press

Lim E; Goel S; Winer EP, 2015, 'Adjuvant chemotherapy in breast cancer', in Breast Disease Comprehensive Management, pp. 335 - 351, http://dx.doi.org/10.1007/978-1-4939-1145-5_23

Journal articles

Collier AE; Hilz S; Chibly AM; Duan C; Pasquina LW; Sun X; Chavez-MacGregor M; Bardia A; Martín M; Lim E; Sohn J; Pérez-Moreno PD; Fernando TM; Moore HM, 2026, 'ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer', Nature Communications, 17, http://dx.doi.org/10.1038/s41467-026-70335-0

Fernandez KJ; Sultani G; Nobis M; Gloss B; Eshraghi L; McCart Reed AE; Alexandrou S; Lee C; Roden DL; Jones EI; Simad MH; Millar EKA; Bartonicek N; Oakes SR; Valdes-Mora F; Colino-Sanguino Y; Mok ETY; Williams HL; Kutasovic JR; Cummings MC; Stoehr J; Lee V; Harvey K; Wu S; Lakhani SR; Simpson PT; Cox TR; Ooms LM; Mitchell CA; Salomon R; Swarbrick A; Gallego-Ortega D; Lim E; Timpson P; Caldon CE, 2026, 'Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling', Nature Communications, 17, http://dx.doi.org/10.1038/s41467-026-70683-x

Liang J; Ong C; Heslop K; Guan J; Kameswaran V; Daniel B; Shi M; Liang Y; Giltnane JM; Aimi J; Chang CW; Gates MR; Eng-Wong J; Perez-Moreno P; Jhaveri KL; Turner NC; Lim E; Metcalfe C; Moore HM, 2026, 'Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER+ HER2− locally-advanced or metastatic breast cancer', Nature Communications, 17, http://dx.doi.org/10.1038/s41467-026-71233-1

Bidard FC; Barrios C; Bianchini G; Brufsky AM; Chia S; Cortes J; Cristofanilli M; Curigliano G; Dawood S; Fasching PA; Gerratana L; Giordano A; Ignatiadis M; Iwata H; Janni W; Lim E; Kalinsky K; Ma CX; Mayer EL; Medford AJ; Mouabbi JA; O’Shaughnessy J; Park YH; Pascual J; Razavi P; Sammons S; Sandoval JL; Sisca L; Tarantino P; Wander SA; Werutsky G; Turner NA, 2026, 'SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer', Npj Breast Cancer, 12, http://dx.doi.org/10.1038/s41523-026-00967-4

Chen J; Zhang H; Ruan T; Wu SZ; Slapetova I; Millar E; Graham PH; Lynch J; Browne LH; Lim E; Swarbrick A, 2026, 'Stromal cell subsets modulate T-cell infiltration in early breast cancer.', Cancer Res Commun, http://dx.doi.org/10.1158/2767-9764.CRC-25-0709

Howard F; Fasching PA; Park YH; Santa-Maria CA; Lim E; Sparano JA; Lustberg MB; Bachelot T; Blyuss O; Brezden-Masley C; Akdere M; Ye F; Kurz C; Dominguez Castro P; Razavi P, 2026, 'Predicting recurrence and survival in hormone receptor–positive (HR+)/HER2-negative (HER2–) early breast cancer (EBC) with machine learning models: Optimization of model complexity.', Journal of Clinical Oncology, 44, pp. 562 - 562, http://dx.doi.org/10.1200/jco.2026.44.16_suppl.562

Redfern A; Lim E; Lakhani S; Pathmanathan N; Selva-Nayagam S; McCarthy N; Yeo B; Dessauvagie B; Farshid G, 2026, 'Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer: Practical Considerations for Medical Oncologists and Pathologists in Australia', Asia Pacific Journal of Clinical Oncology, 22, pp. 381 - 391, http://dx.doi.org/10.1111/ajco.70069

Serrano A; Weber TS; Berthelet J; Ftouni S; El-Saafin F; Lee S; Lim E; Charafe-Jauffret E; Ginestier C; Williams D; Hollande F; Yeo B; Dawson SJ; Naik SH; Merino D, 2026, 'Genetic barcoding uncovers the clonal makeup of solid and liquid biopsies and their ability to capture intra-tumoral heterogeneity', Molecular Systems Biology, 22, pp. 659 - 684, http://dx.doi.org/10.1038/s44320-026-00194-w

Kim HJ; Kiedik B; Harvey K; Kanwal S; Douglas J; Reeves J; Lobanov A; Roden DL; Van Der Leij S; Hui MN; Al’Khafaji A; Lim E; Grimmond SM; Lundeberg J; Perou CM; Swarbrick A, 2026, 'A comprehensive multiomics atlas of treatment-naïve breast cancer uncovers co-occurring tumor-immune ecosystems driving immune hot and cold phenotypes', CANCER RESEARCH, 86, http://dx.doi.org/10.1158/1538-7445.AM2026-7282

Lobanov AV; Kim HJ; Kanwal S; Harvey K; Reeves J; Batten M; Kiedik B; Roden DL; Hui MN; Stewart KP; Hofmann O; O’Toole S; Lim E; Grimmond SM; Swarbrick A; Perou CM, 2026, 'scSubtype2.0: Predictor of breast cancer molecular subtypes at single cell resolution.', CANCER RESEARCH, 86, http://dx.doi.org/10.1158/1538-7445.AM2026-44

Jhaveri KL; Neven P; Casalnuovo ML; Kim SB; Tokunaga E; Aftimos P; Saura C; O’Shaughnessy J; Harbeck N; Carey LA; Curigliano G; Watanabe J; Lim E; Huang J; Qingyuan Z; Llombart-Cussac A; Huang C; Desai B; Limay Y; Wang XA; Cao S; Bidard FC, 2026, 'Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial', Annals of Oncology, 37, pp. 532 - 543, http://dx.doi.org/10.1016/j.annonc.2025.11.018

Watt AC; Ahn A; Blyth C; Dixon-Douglas J; Ambani K; Coulson R; Taylor M; Chan K; Dietrich C; Russ BE; Ramm S; Mahendra CA; Lu K; Pires N; Lim E; Chandarlapaty S; Andre F; Goel S, 2026, 'Abstract GS3-06: Rb Functions as a Transcriptional Activator of ER Targets Following CDK4/6 Inhibition in Luminal Breast Cancer', Clinical Cancer Research, 32, http://dx.doi.org/10.1158/1557-3265.sabcs25-gs3-06

Jhaveri KL; Neven P; Casalnuovo M; Kim S; Tokunaga E; Aftimos P; Saura C; O'Shaughnessy J; Harbeck N; Carey LA; Curigliano G; Watanabe J; Lim E; Huang J; Qingyuan Z; Llombart-Cussac A; Huang C; Desai B; Wang X; Cao S; Bidard F; Limay Y, 2026, 'Abstract GS3-08: Imlunestrant with or without abemaciclib in advanced breast cancer (ABC): Updated efficacy results from the phase 3 EMBER-3 trial', Clinical Cancer Research, 32, http://dx.doi.org/10.1158/1557-3265.sabcs25-gs3-08

BIDARD F; Jhaveri K; Kim S; Tokunaga E; Aftimos P; Saura C; O’Shaughnessy J; Harbeck N; Curigliano G; Llombart-Cussac A; Lim E; Im S; Bando H; Neven P; Estrem ST; Nguyen B; Cao S; Makena M; Desai B; Carey LA, 2026, 'Abstract PD5-08: Circulating Tumour DNA (ctDNA) Dynamics From Patients With ER+, HER2- Advanced Breast Cancer in the Phase 3 EMBER-3 Trial', Clinical Cancer Research, 32, http://dx.doi.org/10.1158/1557-3265.sabcs25-pd5-08

Metzger O; Mandrekar S; Dockter T; Gianni L; Ciruelos E; De Michele A; Gligorov J; Lim E; Loibl S; Farré XG; Lynce F; Lanzillotti J; Carey L; Goel S; Partridge A; Winer E, 2026, 'Abstract RF4-01: Central Nervous System Outcomes from the Phase III PATINA Trial (AFT-38)', Clinical Cancer Research, 32, http://dx.doi.org/10.1158/1557-3265.sabcs25-rf4-01

Metzger O; Mandrekar S; Goel S; Gligorov J; Lim E; Ciruelos E; Loibl S; Dockter T; Gonzàlez Farré X; Francis PA; Lynce F; Lanzillotti J; Dufrane C; Wall A; Strand C; Krop I; Vaz-Luis I; Tripathy D; Loi S; Prat A; Goetz M; Escrivá-De-Romaní S; Porter D; Spoenlein J; Stover DG; Sardesai S; Heudel P; Koehler M; Huang Bartlett C; Holynskyj A; Gopalakrishna P; Gauthier E; Delaloge S; Miller K; Winer EP; Gianni L; Partridge AH; Demichele A; Carey LA, 2026, 'Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer', New England Journal of Medicine, 394, pp. 451 - 462, http://dx.doi.org/10.1056/NEJMoa2511218

Howard FM; Fasching PA; Santa-Maria CA; Lim E; Sparano JA; Lustberg MB; Bachelot T; Blyuss O; Brezden-Masley C; Park YH; Akdere M; Ye F; Pantoja K; Kurz C; Castro PD; Razavi P, 2026, 'Machine Learning-Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2− Early Breast Cancer Using Real-World and NATALEE Data', Clinical Cancer Research, 32, pp. 428 - 437, http://dx.doi.org/10.1158/1078-0432.CCR-25-1946

Lim E; Yu J; Li C; Shah MD; Eng-Wong J; Pérez-Moreno PD; Jhaveri K, 2026, 'Optimizing dose selection in oncology: the rationale for the clinical dose selection of giredestrant, an oral selective estrogen receptor degrader', Expert Opinion on Investigational Drugs, 35, pp. 19 - 28, http://dx.doi.org/10.1080/13543784.2026.2613290

Howard FM; Fasching PA; Park YH; Santa-Maria CA; Lim E; Sparano J; Lustberg M; Di Meglio A; Blyuss O; Brezden-Masley C; Akdere M; Ye F; Kurz C; Castro PD; Razavi P, 2026, '50P Impact of prior adjuvant chemotherapy (CT) on machine learning prediction of distant recurrence (DR) in HR+/HER2– early breast cancer (EBC)', ESMO Open, 11, pp. 107011 - 107011, http://dx.doi.org/10.1016/j.esmoop.2026.107011

Alves CL; Karimi L; Terp MG; Jakobsen MK; Zhou FH; Policastro B; Nissen N; Johansen LE; Ravnsborg T; Eshraghi L; Tamboowala S; Jensen ON; Lim E; Ditzel HJ, 2025, 'Dual PI3K/mTOR inhibition is required to combat resistance to CDK4/6 inhibitor and endocrine therapy in PIK3CA-mutant breast cancer', Science Translational Medicine, 17, http://dx.doi.org/10.1126/scitranslmed.adp5088

Alexandrou S; Lee CS; Fernandez KJ; Wiharja CE; Eshraghi L; Reeves J; Reed DA; Portman N; Phan Z; Milioli HH; Nikolic I; Cadell AL; Croucher DR; Simpson KJ; Lim E; Hickey TE; Millar EKA; Alves CL; Ditzel HJ; Caldon CE, 2025, 'JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer', Journal of Experimental and Clinical Cancer Research, 44, http://dx.doi.org/10.1186/s13046-025-03466-9

Childs S; Semba R; Haggstrom L; Lim E, 2025, 'Integrating Molecular Phenotyping into Treatment Algorithms for Advanced Oestrogen Receptor-Positive Breast Cancer', Cancers, 17, http://dx.doi.org/10.3390/cancers17193174

Cai Z; Boys EL; Noor Z; Aref AT; Xavier D; Lucas N; Williams SG; Koh JMS; Poulos RC; Wu Y; Dausmann M; Mackenzie KL; Aguilar-Mahecha A; Armengol C; Barranco MM; Basik M; Bowman ED; Clifton-Bligh R; Connolly EA; Cooper WA; Dalal B; Defazio A; Filipits M; Flynn PJ; Dinny Graham J; George J; Gill AJ; Gnant M; Habib R; Harris CC; Harvey K; Horvath LG; Jackson C; Kohonen-Corish MRJ; Lim E; Liu J; Long GV; Lord RV; Mann GJ; McCaughan GW; Morgan L; Murphy L; Nagabushan S; Nagrial A; Navinés J; Panizza BJ; Samra JS; Scolyer RA; Souglakos J; Swarbrick A; Thomas D; Balleine RL; Hains PG; Robinson PJ; Zhong Q; Reddel RR, 2025, 'Federated Deep Learning Enables Cancer Subtyping by Proteomics', Cancer Discovery, 15, pp. 1803 - 1818, http://dx.doi.org/10.1158/2159-8290.CD-24-1488

Haggstrom L; Middleton K; Segara D; Ong A; Bingham J; Carson E-K; Kiely BE; Sabanathan D; Saw K; Siu MT; Serrano A; Eshraghi L; O'Toole S; Mann B; Lindeman GJ; Swarbrick A; Tilley W; Coates AS; Parker A; Lim E, 2025, 'The WinPro trial: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer.', JOURNAL OF CLINICAL ONCOLOGY, 43, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.513

Sabahi Z; Nguyen A; Wong K; Li S; Papa N; Lim E; Dear RF; Menzies AM; Boyle F; Antill Y; Kiely BE; Forster BC; Mak C; Adams D; Pugliano L; Spillane A; Sharma S; Hickey A; Poole A; Agrawal S; Khan S; Ayati N; Emmett L, 2025, 'Diagnostic Potential of 68Ga-NeoB PET/CT with Estrogen Receptor– and Progesterone Receptor–Positive Breast Cancer Undergoing Staging or Restaging for Metastatic Disease', Journal of Nuclear Medicine, 66, pp. 700 - 706, http://dx.doi.org/10.2967/jnumed.124.268896

Gough M; Kwah KKX; Khan T; Ghosh S; Sun B; Lee CYJ; Sokolowski KA; Tse BWC; Wickramasuriya L; Ferguson K; Rogers R; Goh JB; Fletcher NL; Houston ZH; Thurecht KJ; Bray LJ; Liu C; Pyke C; Lim E; Snell CE; He Y; Hooper JD; Kryza T, 2025, 'Receptor CDCP1 Is a Potential Target for Personalized Imaging and Treatment of Poor Outcome HER2+, Triple-Negative, and Metastatic ER+/HER2− Breast Cancers', Clinical Cancer Research, 31, pp. 1504 - 1519, http://dx.doi.org/10.1158/1078-0432.CCR-24-2865

Jhaveri KL; Neven P; Casalnuovo ML; Kim SB; Tokunaga E; Aftimos P; Saura C; O'Shaughnessy J; Harbeck N; Carey LA; Curigliano G; Llombart-Cussac A; Lim E; García Tinoco MDLL; Sohn J; Mattar A; Zhang Q; Huang CS; Hung CC; Martinez Rodriguez JL; Ruíz Borrego M; Nakamura R; Pradhan KR; Cramer Von Laue C; Barrett E; Cao S; Wang XA; Smyth LM; Bidard FC, 2025, 'Imlunestrant with or without Abemaciclib in Advanced Breast Cancer', New England Journal of Medicine, 392, pp. 1189 - 1202, http://dx.doi.org/10.1056/NEJMoa2410858

Jhaveri KL; Lim E; Jeselsohn R; Ma CX; Hamilton EP; Osborne C; Bhave M; Kaufman PA; Beck JT; Sanchez LM; Parajuli R; Wang H-C; Tao JJ; Im S-A; Harnden K; Yonemori K; Dhakal A; Neven P; Aftimos P; Pierga J-Y; Lu Y-S; Larson T; Jerez Y; Sideras K; Sohn J; Kim S-B; Saura C; Bardia A; Sammons SL; Bacchion F; Li Y; Yuen E; Estrem ST; Rodrik-Outmezguine V; Nguyen B; Ismail-Khan R; Smyth L; Beeram M, 2025, 'Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study (vol 42, 35, 2024)', JOURNAL OF CLINICAL ONCOLOGY, 43, pp. 114 - 114, http://dx.doi.org/10.1200/JCO-24-02470

Toi M; Kim S-B; Chiu JWY; Broom R; Sagara Y; Chao T-Y; Liu Z; Sherwood S; Huynh T; Wei RJ; Lim E; Yap Y-S, 2025, '201P Abemaciclib (abema) combined with adjuvant endocrine therapy (ET) in patients from monarchE in Asia with high-risk early breast cancer (EBC)', ESMO Open, 10, pp. 104755 - 104755, http://dx.doi.org/10.1016/j.esmoop.2025.104755

Jhaveri K; Pegram M; Neven P; Curigliano G; Spring LM; Gligorov J; Schlam I; Harbeck N; Juric D; Lim E; Wang S; Santarsiero L; Akdere M; Ye F; Kim J; Cardoso F, 2025, '219P Real-world (RW) risk of recurrence in pre- and postmenopausal patients (pts) with HR+/HER2− early breast cancer (EBC) eligible for NATALEE', ESMO Open, 10, pp. 104773 - 104773, http://dx.doi.org/10.1016/j.esmoop.2025.104773

Vaz-Luis IV; Mazza G; Gligorov J; Lim E; Ciruelos E; Loibl S; DeMichele A; Fruth B; Farre XG; Francis P; Lynce F; Chien J; Delaloge S; Miller KD; Winer E; Mandrekar SJ; Goel S; Carey L; Partridge AH; Metzger O, 2025, '485MO Health-related quality of life (HRQoL) from the PATINA trial (AFT-38): Impact of adding palbociclib to HER2 and endocrine therapy (ET) after induction in HR+/HER2+ metastatic breast cancer (MBC)', Annals of Oncology, 36, pp. S378 - S378, http://dx.doi.org/10.1016/j.annonc.2025.08.909

Gemma C; Lai CF; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Raafat S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin LA; Lim E; Charles Coombes R; Pruneri G; Buluwela L; Ali S, 2024, 'Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer', Cancer Research, 84, pp. 4283 - 4297, http://dx.doi.org/10.1158/0008-5472.CAN-24-0013

Jhaveri KL; Lim E; Jeselsohn R; Ma CX; Hamilton EP; Osborne C; Bhave M; Kaufman PA; Beck JT; Manso Sanchez L; Parajuli R; Wang HC; Tao JJ; Im SA; Harnden K; Yonemori K; Dhakal A; Neven P; Aftimos P; Pierga JY; Lu YS; Larson T; Jerez Y; Sideras K; Sohn J; Kim SB; Saura C; Bardia A; Sammons SL; Bacchion F; Li Y; Yuen E; Estrem ST; Rodrik-Outmezguine V; Nguyen B; Ismail-Khan R; Smyth L; Beeram M, 2024, 'Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study', Journal of Clinical Oncology, 42, pp. 4173 - 4186, http://dx.doi.org/10.1200/JCO.23.02733

Peters TJ; Meyer B; Ryan L; Achinger-Kawecka J; Song J; Campbell EM; Qu W; Nair S; Loi-Luu P; Stricker P; Lim E; Stirzaker C; Clark SJ; Pidsley R, 2024, 'Characterisation and reproducibility of the HumanMethylationEPIC v2.0 BeadChip for DNA methylation profiling', BMC Genomics, 25, http://dx.doi.org/10.1186/s12864-024-10027-5

Hosseinzadeh L; Kikhtyak Z; Laven-Law G; Pederson SM; Puiu CG; D’Santos CS; Lim E; Carroll JS; Tilley WD; Dwyer AR; Hickey TE, 2024, 'The androgen receptor interacts with GATA3 to transcriptionally regulate a luminal epithelial cell phenotype in breast cancer', Genome Biology, 25, http://dx.doi.org/10.1186/s13059-023-03161-y

Yap N; Wong V; Morton C; de Boer R; Baron-Hay S; Blum R; Forster B; Chua S; Clarke K; Cuff K; Green M; Lim E; Mok K; Nott L; Nottage M; Tafreshi A; Tsoi D; Uccellini A; Gibbs P; Lok SW, 2024, 'Medicine Access Programmes: what do patients think – a patient-reported outcome study on ribociclib in metastatic breast cancer in Australia', Internal Medicine Journal, 54, pp. 1894 - 1897, http://dx.doi.org/10.1111/imj.16536

Sriravindrarajah A; Hurwitz J; Lim E; Greenfield JR, 2024, 'Hyperglycemia secondary to phosphatidylinositol-3 kinase (PI3K) inhibition', Endocrinology Diabetes and Metabolism Case Reports, 2024-October, http://dx.doi.org/10.1530/EDM-24-0040

Martín M; Lim E; Chavez-MacGregor M; Bardia A; Wu J; Zhang Q; Nowecki Z; Cruz FM; Safin R; Kim SB; Schem C; Montero AJ; Khan S; Bandyopadhyay R; Moore HM; Shivhare M; Patre M; Martinalbo J; Roncoroni L; Pérez-Moreno PD; Sohn J, 2024, 'Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study', Journal of Clinical Oncology, 42, pp. 2149 - 2160, http://dx.doi.org/10.1200/JCO.23.01500

Filipe EC; Velayuthar S; Philp A; Nobis M; Latham SL; Parker AL; Murphy KJ; Wyllie K; Major GS; Contreras O; Mok ETY; Enriquez RF; McGowan S; Feher K; Quek LE; Hancock SE; Yam M; Tran E; Setargew YFI; Skhinas JN; Chitty JL; Phimmachanh M; Han JZR; Cadell AL; Papanicolaou M; Mahmodi H; Kiedik B; Junankar S; Ross SE; Lam N; Coulson R; Yang J; Zaratzian A; Da Silva AM; Tayao M; Chin IL; Cazet A; Kansara M; Segara D; Parker A; Hoy AJ; Harvey RP; Bogdanovic O; Timpson P; Croucher DR; Lim E; Swarbrick A; Holst J; Turner N; Choi YS; Kabakova IV; Philp A; Cox TR, 2024, 'Tumor Biomechanics Alters Metastatic Dissemination of Triple Negative Breast Cancer via Rewiring Fatty Acid Metabolism', Advanced Science, 11, http://dx.doi.org/10.1002/advs.202307963

Hamilton E; Neven P; Pistilli B; Beeram M; Borges V; Campone M; Guimaraes JLM; Foukakis T; Kodahl AR; Lau P; Lim E; Lugowska I; Rychlik G; Gresty C; Miller C; Sommavilla R; Sudhan D; Rugo H, 2024, 'Capivasertib plus cyclindependent kinase 4/6 inhibitor and fulvestrant in hormone receptorpositive/human epidermal growth factor receptor 2-negative advanced breast cancer: updated Phase 1b analysis from CAPItello292', CANCER RESEARCH, 84, http://dx.doi.org/10.1158/1538-7445.SABCS23-PS12-09

Collier A; Bardia A; Sohn JH; Lim E; Chavez M; Martin M; Martinalbo J; Perez-Moreno P; Moore H, 2024, 'Circulating tumor DNA dynamics in acelERA Breast Cancer: a Phase II study of giredestrant for estrogen receptor-positive, HER2-negative, previously treated advanced breast cancer', CANCER RESEARCH, 84, http://dx.doi.org/10.1158/1538-7445.SABCS23-PO1-05-07

Jhaveri K; Lien YTK; Turner N; Lim E; Cannon M; Anziano R; Langenhorst J; Yoshida K; Malhi V; Gates M; Eng-Wong J; Li C; Shah M; Perez-Moreno P; Yu J; Bardia A, 2024, 'Exposureresponse analyses of GO39932: a Phase Ia/b study of giredestrant in estrogen receptor-positive, HER2negative, locally advanced or metastatic breast cancer', CANCER RESEARCH, 84, http://dx.doi.org/10.1158/1538-7445.SABCS23-PO4-04-11

Jhaveri K; Lim E; Jeselsohn R; Ma C; Hamilton E; Osborne C; Bhave M; Kaufman P; Beck JT; Manso L; Parajuli R; Wang H-C; Tao J; Dhakal A; Pierga J-Y; Lu Y-S; Larson T; Gilarranz YJ; Ismail-Khan R; Bacchion F; Karacsonyi C; Li Y; Estrem ST; Nguyen B; Beeram M, 2024, 'Imlunestrant monotherapy and in combination with abemaciclib, with or without an aromatase inhibitor, in estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC): updated results from the EMBER study', CANCER RESEARCH, 84, http://dx.doi.org/10.1158/1538-7445.SABCS23-PS15-09

Liang J; Ong C; Giltnane J; Aimi J; Chang C-W; Gates M; Eng-Wong J; Perez-Moreno P; Jhaveri K; Lim E; Turner N; Moore H, 2024, 'Key drivers of therapeutic response and resistance to giredestrant from GO39932: a Phase Ia/b study in patients with estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer', CANCER RESEARCH, 84, http://dx.doi.org/10.1158/1538-7445.SABCS23-PS17-01

Park KH; Loibl S; Sohn J; Park YH; Jiang Z; Tadjoedin H; Nag S; Saji S; Md. Yusof M; Villegas EMB; Lim EH; Lu YS; Ithimakin S; Tseng LM; Dejthevaporn T; Chen TWW; Lee SC; Galvez C; Malwinder S; Kogawa T; Bajpai J; Brahma B; Wang S; Curigliano G; Yoshino T; Kim SB; Pentheroudakis G; Im SA; Andre F; Ahn JB; Harbeck N, 2024, 'Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer', ESMO Open, 9, http://dx.doi.org/10.1016/j.esmoop.2024.102974

Guarducci C; Nardone A; Russo D; Nagy Z; Heraud C; Grinshpun A; Zhang Q; Freelander A; Leventhal MJ; Feit A; Feit GC; Feiglin A; Liu W; Hermida-Prado F; Kesten N; Ma W; De Angelis C; Morlando A; O'Donnell M; Naumenko S; Huang S; Nguyen QD; Huang Y; Malorni L; Bergholz JS; Zhao JJ; Fraenkel E; Lim E; Schiff R; Shapiro GI; Jeselsohn R, 2024, 'Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor- positive Breast Cancer', Clinical Cancer Research, 30, pp. 1889 - 1905, http://dx.doi.org/10.1158/1078-0432.CCR-23-2975

Back to profile page